Ahmed Sawas, MD
Hematology · New York, NYNPI 1134379043
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $461,309 of the $618,105 with a category attached, or 74.6%. 28 manufacturers reported payments, led by Seagen Inc. at 25.6% of the total. Reporting peaked in 2023 at $148,528 and has fallen 65.1% since, to $51,882 in 2025. Among hematology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 664 payments — averaging $930.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$159K
- Daiichi Sankyo Inc.$145K
- Gilead$100K
- Lilly USA, LLC$85K
- Pfizer$47K
- Acrotech Biopharma Inc.$39K
- plus $45K from 22 others
Across 10 payments — averaging $32,559 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$283K
- E.r. Squibb & Sons, L.L.C.$32K
- Seagen Inc.$10K
- F. Hoffmann-la Roche AG$271
What the payments were for
- Consulting fees$62,44010%
- Speaking & faculty fees$461,30975%
- Grants$10,2302%
- Travel & lodging$70,84911%
- Food & beverage$12,8732%
- Education$4030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 140 | $158,531 |
| Daiichi Sankyo Inc. | 155 | $144,723 |
| Gilead(2 entities) | 82 | $99,574 |
| Lilly USA, LLC | 73 | $84,786 |
| Pfizer | 40 | $46,606 |
| Acrotech Biopharma Inc. | 44 | $38,570 |
| Kyowa Kirin, Inc. | 22 | $16,275 |
| Aurobindo Pharma USA, Inc. | 39 | $14,060 |
| Pharmacyclics LLC, An Abbvie Company | 27 | $6,518 |
| Pharmacosmos Therapeutics Inc. | 11 | $6,099 |
| Secura Bio, Inc. | 5 | $495 |
| Vertex | 1 | $483 |
| Sanofi-aventis U.S. LLC | 2 | $389 |
| Johnson & Johnson | 4 | $274 |
| Clovis Oncology, Inc. | 1 | $124 |
| Novocure Inc. | 1 | $106 |
| Incyte Corporation | 2 | $91 |
| Geron Corporation | 1 | $90 |
| Morphosys, US Inc. | 3 | $56 |
| AstraZeneca | 2 | $53 |
| AbbVie | 2 | $47 |
| Genentech, Inc. | 1 | $39 |
| Adaptive Biotechnologies Corporation | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Amgen | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$618,105 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 18 | $1,064 |
| Prednisone | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
- Adam KittaiNew York$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.